BRIEF published on 02/03/2026 at 12:17, 7 months 9 days ago GeNeuro SA en faillite après la fin du sursis concordataire Biopharmaceutique Faillite GeNeuro Sursis Concordataire Tribunal De Genève
BRIEF published on 02/03/2026 at 12:17, 7 months 9 days ago GeNeuro SA bankrupt after the end of the composition moratorium Biopharmaceutical Bankruptcy GeNeuro Geneva Court Concordat Moratorium
BRIEF published on 02/03/2026 at 12:14, 7 months 9 days ago GeNeuro SA déclare faillite suite à un moratoire sur la dette Biopharmaceutique Faillite GeNeuro SA Décision De Justice Moratoire Sur La Dette
BRIEF published on 02/03/2026 at 12:14, 7 months 9 days ago GeNeuro SA Declares Bankruptcy Following Debt Moratorium Biopharmaceutical Bankruptcy Court Ruling GeNeuro SA Debt Moratorium
PRESS RELEASE published on 02/03/2026 at 12:12, 7 months 9 days ago INFORMATIONS PRIVILÉGIÉES / AUTRES COMMUNIQUÉS GeNeuro SA annonce la fin du sursis concordataire et l'ouverture de la procédure de faillite. Le Tribunal de première instance de Genève a prononcé la faillite de GeNeuro SA malgré les démarches entreprises pendant le sursis Restructuration Faillite GeNeuro SA Développement Thérapeutique Sursis Concordataire
PRESS RELEASE published on 02/03/2026 at 12:09, 7 months 9 days ago INSIDE INFORMATION / OTHER NEWS RELEASES GeNeuro SA announces the end of debt moratorium and commencement of bankruptcy proceedings after Geneva Court ruling. Further details in official publications Biopharmaceutical Company GeNeuro SA Bankruptcy Proceedings Debt Moratorium Geneva Court Ruling
BRIEF published on 01/23/2026 at 11:05, 7 months 20 days ago GeNeuro SA Suspends Trading Ahead of Court Ruling Euronext Paris Trading Suspension GeNeuro Debt Moratorium Geneva Court
BRIEF published on 01/23/2026 at 11:05, 7 months 20 days ago Temporary suspension of trading of GeNeuro SA shares on Euronext Paris Restructuring GeNeuro SA Geneva Court Trading Suspended Concordat Moratorium
BRIEF published on 01/23/2026 at 11:05, 7 months 20 days ago GeNeuro SA suspend ses échanges en attendant une décision de justice Euronext Paris GeNeuro Suspension Des Échanges Moratoire Sur La Dette Cour De Genève
BRIEF published on 01/23/2026 at 11:05, 7 months 20 days ago Suspension temporaire de la cotation des actions GeNeuro SA sur Euronext Paris Restructuration GeNeuro SA Cotation Suspendue Sursis Concordataire Tribunal De Genève
Published on 09/12/2026 at 02:35, 11 hours ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 35 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 30 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 10 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 35 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 5 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 20 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 25 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 17 hours 50 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 20 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
